Medication Guide

Prescription Info

Instructions for Use

Treating patients on HUMIRA (adalimumab)?
Consider a biosimilar called HADLIMA. HADLIMA is indicated for
the treatment of moderately to severely active ulcerative colitis in adult patients.
Limitations of Use:
The effectiveness of HADLIMA has not been established in patients who have lost response to or were intolerant to tumor necrosis factor (TNF) blockers. Dov, a real patient
with moderately to
severely active ulcerative colitis who switched from HUMIRA (adalimumab)
to HADLIMA, an
FDA-approved interchangeable
biosimilar to HUMIRA. Cost and coverage
for HADLIMA is
dependent on the
terms and conditions
of individual insurance benefits, including any applicable deductible, co-insurance, or
co-payment. Based on analysis of
actual patient claims processed from July 2023 to August 2024, with the average
out-of-pocket costs being $215 vs $48
for HUMIRA and HADLIMA, respectively. Consider which
patients may benefit
from switching to HADLIMA today.